Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
12/06/26	1.100 €	+0.92%	36,000
11/06/26	1.090 €	-0.46%	25,000
10/06/26	1.095 €	0.00%	0
09/06/26	1.095 €	0.00%	11,000
08/06/26	1.095 €	-0.45%	21,000

Real-time Borsa Italiana

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Borsa Italiana Other stock markets 16:45:00 12/06/2026 BST			5-day change	1st Jan Change
1.100 ^EUR	+0.92%		0.00%	-25.17%

06-04	Equities trend higher; banks lead gains on the MIB	AN
05-22	European markets rebound; STM and Stellantis lead gains	AN

Market Cap	9.29M 10.75M 8.56M 8.01M 15.01M 1.02B 15.24M 101M 39.4M 497M 40.35M 39.49M 1.72B	P/E Ratio 2024	30.8x	P/E Ratio 2025	17x
Enterprise Value	9.58M 11.09M 8.83M 8.27M 15.49M 1.05B 15.73M 104M 40.65M 513M 41.64M 40.75M 1.78B	EV / Sales 2024	1.79x	EV / Sales 2025	1.32x
Free-Float	18.98%	Yield 2024 *	-	Yield 2025	-

06-04	Equities trend higher; banks lead gains on the MIB	AN
05-22	European markets rebound; STM and Stellantis lead gains	AN
05-21	Laboratorio Farmaceutico Erfo reports stable first-quarter revenue year-on-year	AN
05-21	Laboratorio Farmaceutico Erfo Q1 EBITDA adj. EUR 0.5 mln	RE
05-21	European markets set for lower open; focus on manufacturing PMIs	AN
04-20	Brent rebounds; futures signal risk-off sentiment	AN
04-17	Greenlight on Hormuz sparks global equity rally	AN
04-12	Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Laboratorio Farmaceutico Erfo posts triple-digit profit growth in 2025	AN
03-06	IG Futures Point to Higher European Markets	AN
03-05	US-Iran Conflict Fuels Commodity Rally; Mib Slides	AN
03-05	Active Markets; Traders Unconvinced by Nexi	AN
02-23	Europe Expected to Open Lower Amid US Tariff Uncertainty	AN

04-09	Laboratorio Farmaceutico Erfo S p A : Investor Presentation Erfo SpA FY2025 (ENG)	PU
21/10/25	Laboratorio Farmaceutico Erfo S p A : 2025 10 20-ERFO-NextGEMS	PU
29/08/25	Laboratorio Farmaceutico Erfo S p A : 2025 08 28 ERFO - Press release KPI 1H 2025	PU
04/06/25	Laboratorio Farmaceutico Erfo S p A : KT Erfo 1Q25 Final	PU
19/05/25	Laboratorio Farmaceutico Erfo S p A : KT Erfo FY24 Final	PU

Laboratorio Farmaceutico Erfo S.p.A. Share Price

Stocks

ERFO

IT0005497885

Pharmaceuticals

Valuation: Laboratorio Farmaceutico Erfo S.p.A.

Chart: Laboratorio Farmaceutico Erfo S.p.A.

Latest news : Laboratorio Farmaceutico Erfo S.p.A.

Press Releases: Laboratorio Farmaceutico Erfo S.p.A.

News in other languages: Laboratorio Farmaceutico Erfo S.p.A.

Quotes and Performance

Course Extremes

Managers and Directors: Laboratorio Farmaceutico Erfo S.p.A.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06-04	Borse rialziste; bene i bancari sul MIB
05-22	Tornano gli acquisti in Europa; su STM e Stellantis
05-21	Laboratorio Farmaceutico Erfo chiude trimestre stabile su base annua
05-21	Laboratorio Farmaceutico Erfo S p A : 2026 05 21 ERFO - CS Dati gestionali Q1 2026 ITA-ENG
05-21	Europee attese giù; focus su PMI manifatturiero

1 day	+0.92%
Current month	+0.92%
1 month	-2.22%
3 months	-5.17%
6 months	-26.42%
Current year	-25.17%

1 week	1.07	1.11
1 month	1.06	1.18
Current year	1.01	1.6
1 year	1.01	1.8
3 years	0.88	1.8
5 years	0.88	3.3
10 years	0.88	3.3

Manager	Title	Age	Since
Alessandro Cutè CEO	Chief Executive Officer	55	31/12/2012
Daniele Travisano DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Alessandro Cutè CHM	Chairman	55	31/12/2012
Flavio Corpina BRD	Director/Board Member	47	31/12/2016
Fabio Giuffre BRD	Director/Board Member	45	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
12-15	Alessandro Cutè	Sell	Chief Executive Officer	322,000	3.5778%
12-15	Alessandro Cutè	Sell	Chief Executive Officer	968,000	10.7556%
28/06/22	Alessandro Cutè	Others	Chief Executive Officer	300,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LABORATORIO FARMACEUTICO ERFO S.P.A.	+0.92%	0.00%	-8.71%	-6.78%	10.7M
ELI LILLY AND COMPANY	-1.34%	+1.12%	+40.89%	+156.92%	1,035B
JOHNSON & JOHNSON	+0.63%	+3.00%	+53.04%	+49.94%	574B
ABBVIE INC.	+1.05%	-0.01%	+18.08%	+64.96%	397B
ROCHE HOLDING AG	+0.58%	+0.77%	+21.19%	+15.95%	324B
ASTRAZENECA PLC	-0.85%	-2.86%	+22.05%	+13.80%	281B
NOVARTIS AG	+0.44%	+3.48%	+24.48%	+34.39%	278B
NOVO NORDISK A/S	+1.66%	+5.61%	-44.67%	-47.49%	193B
AMGEN INC.	+0.24%	+1.53%	+19.39%	+63.29%	191B
GILEAD SCIENCES, INC.	-0.12%	-2.77%	+12.07%	+61.29%	156B
Average	+0.34%	+1.07%	+15.78%	+40.63%	342.99B
Weighted average by Cap.	-0.05%	+2.39%	+28.22%	+72.31%

	2024	2025
Net sales	6.03M 6.98M 5.56M 5.2M 9.75M 664M 9.9M 65.64M 25.59M 323M 26.21M 25.65M 1.12B	9.73M 11.27M 8.97M 8.39M 15.73M 1.07B 15.97M 106M 41.28M 521M 42.29M 41.39M 1.8B
Net income	353K 408K 325K 304K 570K 38.83M 579K 3.84M 1.5M 18.9M 1.53M 1.5M 65.44M	737K 853K 679K 636K 1.19M 81.1M 1.21M 8.02M 3.13M 39.48M 3.2M 3.13M 137M
Net Debt	5.77K 6.68K 5.31K 4.97K 9.32K 635K 9.47K 62.75K 24.47K 309K 25.06K 24.53K 1.07M	295K 342K 272K 255K 478K 32.51M 485K 3.21M 1.25M 15.82M 1.28M 1.26M 54.79M